ALUNBRIG Approved by European Commission as Treatment for Patients with ALK+ NSCLC
kalhh / Pixabay

ALUNBRIG Approved by European Commission as Treatment for Patients with ALK+ NSCLC

  According to a release on Biospace, the European Commission (EC) has approved Takeda Pharmaceutical's ALUNBRIG (brigatinib) as treatment for patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer…

Continue Reading ALUNBRIG Approved by European Commission as Treatment for Patients with ALK+ NSCLC

How This Family is Raising Awareness for Progressive Familial Intrahepatic Cholestasis

Shannon and Todd Palmatier have three children, two of which have progressive familial intrahepatic cholestasis (PFIC). Their sons' diagnoses have brought the lack of knowledge and advocacy to the attention…

Continue Reading How This Family is Raising Awareness for Progressive Familial Intrahepatic Cholestasis
Parkinson’s Disease:  A New Study Focusing on Preventing the Loss of Dopamine Producing Neurons
source: pixabay.com

Parkinson’s Disease:  A New Study Focusing on Preventing the Loss of Dopamine Producing Neurons

  The drug levodopa and most other therapies developed over the years for Parkinson's disease have been centered on correcting the lack of dopamine. Researchers acknowledge that the reason dopamine…

Continue Reading Parkinson’s Disease:  A New Study Focusing on Preventing the Loss of Dopamine Producing Neurons
Emerald Health Pharmaceuticals Initiates Phase 2 Clinical Study on Systemic Sclerosis
Pexels / Pixabay

Emerald Health Pharmaceuticals Initiates Phase 2 Clinical Study on Systemic Sclerosis

  A news release from Benzinga shares that biotechnology company Emerald Health Pharmaceuticals is beginning a Phase 2 clinical study on EHP-101 as a treatment for patients with systemic sclerosis.…

Continue Reading Emerald Health Pharmaceuticals Initiates Phase 2 Clinical Study on Systemic Sclerosis
Company Starts Compassionate Use Program for an Experimental COVID-19 Treatment
source: pixabay.com

Company Starts Compassionate Use Program for an Experimental COVID-19 Treatment

According to a story from gurufocus.com, the biotechnology company Capricor Therapeutics has recently announced the initiation of a compassionate use program for its experimental drug CAP-1002. This drug will be…

Continue Reading Company Starts Compassionate Use Program for an Experimental COVID-19 Treatment